Comparing Cognitive Behavioral Therapy and Lemborexant Medication for Treating Different Types of Chronic Insomnia in Adults
Led by Laval University · Updated on 2025-04-09
90
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effects of Cognitive Behavioral Therapy for Insomnia CBT-I and the medication lemborexant compared to a placebo in adults with insomnia disorder who also have symptoms of anxiety or depression. The study aims to see how these treatments affect sleep and mental health, and whether different types of insomnia, based on sleep duration, influence treatment outcomes. This is an interventional study involving random assignment to treatment groups.
Participants will be randomly assigned to one of three groups CBT-I therapy, lemborexant medication, or placebo medication. CBT-I involves six therapy sessions over eight weeks, with weekly sessions at first and then biweekly. Those in the medication groups will take 5 to 10 mg of lemborexant or a matching placebo at bedtime for eight weeks, with six consultation visits to monitor response and side effects. Dose adjustment from 5 mg to 10 mg may occur after the first week if needed.
Participants will undergo assessments at baseline, after treatment, and at six months follow-up. They will complete sleep diaries nightly before, during, and after treatment to track sleep onset, wake time, total sleep time, and sleep efficiency. Researchers will also measure insomnia severity, depressive and anxiety symptoms, mental well-being, fatigue, functional impact of insomnia, and sleep-related beliefs. The study includes safety monitoring and aims to evaluate outcomes over several months.
CONDITIONS
Brief Title
Efficacy of CBT-I and Lemborexant Medication for Different Subtypes of Chronic Insomnia
Research Team
M
Manon Lamy
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Diagnosed with insomnia disorder meeting DSM-5 criteria with an Insomnia Severity Index score above 10
Presence of mild symptoms of anxiety or depression with PHQ-9 score over 4 and/or GAD-7 score over 4
Ability to read and understand French or English
Access to a smartphone, tablet, or computer with home internet connection
You will not qualify if you...
Lifetime diagnosis of any psychotic or bipolar disorder
Untreated psychiatric disorder or risk of suicide
Substance or alcohol use disorder within the past year
Life-threatening or progressive medical illness or neurological degenerative disease
Current use of sleep-promoting medications or cannabis products more than two nights per week
Current use of tricyclic antidepressants, monoamine oxidase inhibitors, or atypical antidepressants
Diagnosis of other sleep disorders besides insomnia
High risk or symptoms of sleep apnea
Irregular sleep schedules with bedtimes after 2:00 AM more than twice per week
Working night shifts more than five nights per month in the last six months
Regular consumption of two or more alcoholic drinks per day
Contraindications to study medication including lung disease, use of strong or moderate CYP3A inducers, pregnancy, breastfeeding
Not using any method of birth control
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 8 weeks
Participants receive either cognitive behavioral therapy for insomnia (CBT-I) with six therapy sessions over 8 weeks, or take medication (lemborexant or placebo) with six consultations over 8 weeks to monitor response and side effects.
6 visits over 8 weeks
Follow-up
Duration - 6 months
Participants complete assessments at 2 weeks post-treatment and at 6 months to monitor insomnia symptoms and other health outcomes.
2 visits (post-treatment and 6-month follow-up)
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Similar Trials
Comparing Common Prescription and Over-the-Counter Medications for Insomnia Treatment in Adults Using a Sequential Randomized Trial Design
Auricular Acupuncture by Village Doctors to Improve Sleep in Older Adults
with Diabetes and High Blood Pressure
Comparing Brief Behavioral Treatment for Insomnia to Progressive Muscle Relaxation in Veterans with PTSD and Insomnia
Comparing Bedtime Restriction Therapy and Cognitive Behavioral Therapy for Insomnia in Adults
Study on Daridorexant for Improving Sleep in People Aged 60 to 85 with Mild Cognitive Impairment or Mild to Moderate Alzheimers Disease and Insomnia
Impact of Evening Vinyasa and Gentle Yoga Sessions on Sleep and Heart Health in Adults with and without Insomnia
Comparing Cognitive Behavioral Therapy and Lemborexant Medication for Treating Different Types of Chronic Insomnia in Adults
A Phase 3 Study Comparing Daily Tasimelteon to Placebo for Treating Insomnia in Children Aged 2 to 17
Using Mental Imagery Rescripting and Memory Reactivation to Treat Insomnia Disorder in Adults Aged 18 to 45
Study of Digital Cognitive Behavioral Therapy and Sauna Blanket Heating for Adults with Insomnia
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Efficacy of cognitive behavioral therapy for insomnia and lemborexant medication for different subtypes of chronic insomnia: study protocol for a randomized controlled trial.